Press Releases Compugen Ltd.

Equities

CGEN

IL0010852080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
2.17 ^USD	-0.91%		-11.07%	+9.60%

May. 30	Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	CI
May. 20	Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	May. 30	PR
Compugen : Reports First Quarter 2024 Results	May. 20	PU
Compugen: Q1 Earnings Snapshot	May. 20	AQ
Compugen Reports First Quarter 2024 Results	May. 20	PR
Compugen : Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential	May. 16	PU
Compugen Appoints David Silberman as Chief Financial Officer	May. 15	PR
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024	May. 06	PR
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	Apr. 26	AQ
Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	Apr. 25	PU
Compugen to Participate in Two Upcoming Investor Conferences	Apr. 03	PR
Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	Mar. 11	PU
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	Mar. 11	PR
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	Mar. 07	AQ
Compugen : To Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	Mar. 06	PU
Compugen: Q4 Earnings Snapshot	Mar. 05	AQ
Compugen : Form 6-K- Fourth quarter and full year 2023 results	Mar. 05	PU
Compugen Reports Fourth Quarter and Full Year 2023 Results	Mar. 05	PR
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024	Feb. 26	PR
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024	Feb. 20	PR
Compugen names new chief medical officer	Feb. 16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Compugen Ltd.

Equities

CGEN

IL0010852080

Press Releases

Filters